-
EPP water-based epoxy primer + polymer modified asphalt fiber reinforced bridge deck waterproof layer construction technology
Time of Update: 2022-08-10
Background technique: In recent years, China's bridge construction has developed rapidly, and the asphalt pavement layer of the bridge deck has become the main bridge deck structure form . However, mo
-
Deck Pharma's first new drug approved in China
Time of Update: 2021-12-26
According to an earlier press release from Deqi Pharmaceuticals, Celiniso is currently the first and only oral XPO1 inhibitor approved by the US FDA and the first to be used for the treatment of multiple myeloma and diffuse large B-cell lymphoma Drugs .
-
Deck Pharmaceuticals obtained US FDA approval of ATG-101 (PD-L1/4-1BB double antibody
Time of Update: 2021-12-09
The approval of the IND enables Deqi Pharmaceuticals to initiate this phase I clinical study, which aims to evaluate the safety and tolerability of ATG-101 in patients with advanced solid tumors and non-Hodgkin's lymphoma .
-
Deck Pharmaceuticals announced the positive preclinical data of two drugs during the SITC annual meeting on November 12
Time of Update: 2021-12-07
At the same time, it is further analyzed by quantitative system pharmacological model Supported the dose selection strategy for the drug-Preclinical data of ERK1/2 inhibitor ATG-017 combination therapy supports future clinical developmentShanghai and Hong Kong November 15, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
-
Deck Pharmaceuticals announced that it will hold its first R&D day on November 16 and 18, 2021
Time of Update: 2021-11-16
November 16th: Online meeting (English session) November 18: Offline meeting will be webcast simultaneously (Chinese session)Shanghai and Hong Kong October 25, 2021/PRNewswire/ - A leading biopharmaceutical company dedicated to the research, development and commercialization of innovative tumor therapies – Deqi Pharmaceutical Co.
-
Deck Pharma announces that the Phase Ib clinical trial application of ATG-008 combined with ATG-010 has been approved in China
Time of Update: 2021-11-14
HK) today announced that the National Medical Products Administration (NMPA) has approved ATG-008 (onatasertib) in combination with ATG-010 (selinexor) for the treatment of relapsed/refractory An open phase Ib study on the dose exploration and safety of diffuse large B-cell lymphoma (rrDLBCL) .
-
Deck Pharmaceuticals and Shanghai Pharmaceutical Holdings reached a cooperation on the commercialization of Celiniso
Time of Update: 2021-08-28
discussed the import authorization, distribution business, supply chain service and innovation of Celiniso (the special English trade name approved by the US FDA: XPOVIO®, the English common name: selinexor) in China Value-added and other levels reached cooperation intentions and signed agreements .
-
Deck Pharma announced that the Phase I clinical trial application of ATG-101 (the first PD-L1/4-1BB
Time of Update: 2021-07-28
HK) today announced that the Bellberry Human Research Ethics Committee (HREC) of Australia has approved ATG-101 for the treatment of metastatic or advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B -NHL) Phase I clinical trial application .
-
Deck Pharmaceuticals (6996.HK) was included in nine benchmark and thematic indexes including the Hang Seng Composite Index
Time of Update: 2021-07-23
The Hang Seng Southbound Stock Connect Index reflects the overall performance of Hong Kong Main Board-listed securities that can be invested through Southbound Stock Connect channels .
-
Deck Pharma appoints Minyoung Kim as General Manager of Deck Korea
Time of Update: 2021-07-18
As the general manager of Deqi Korea, Minyoung will be guided by the company's vision to establish a first-class professional team and actively cooperate with local health organizations to promote the commercialization of innovative products and provide new treatment options for Korean patients .
-
Deck Pharmaceuticals Announces 2020 Results, Its Valuation under Lisence-in Model Doubles 14 Times in Three Years
Time of Update: 2021-07-14
Due to similar business models, Deqi Pharmaceuticals has been benchmarked by many investors with Zai Lab, whose stock price has risen approximately 6 times over the past three years .
-
Deck Pharmaceuticals Announces 2020 Annual Results Progress
Time of Update: 2021-07-14
Progress after the reporting period In January 2021, the company submitted an IND application for the Phase I clinical trial of ATG-019 for the treatment of solid tumors and lymphoma to NMPA .
-
Deck Pharmaceuticals Appoints Kevin Lynch as Chief Medical Officer
Time of Update: 2021-07-14
Kevin will be responsible for the company's clinical development strategy and management of the medical team, and will report directly to Dr.
Kevin used to serve as Vice President and Head of Clinical R&D and Medical Affairs of Celgene Asia Pacific.
-
Military "deck anti-skid coating" is applied in the civil field
Time of Update: 2021-07-10
Over the past three years, Academician Xue Qunji’s research and guidance on high-performance, green and environmentally friendly wear-resistant/lubricating coatings has enabled Haihua Institute, a 52-year-old veteran military-industry supporting enterprise, to rapidly rise on the road of military-civilian integration.
-
Deck Pharma and Callithera Biosciences reached an exclusive global licensing agreement
Time of Update: 2021-07-06
CB-708 is a high-efficiency and highly selective oral CD73 small molecule inhibitor, which is expected to release great potential in single-drug or combination therapy for the treatment of various tumors .